CSL Ltd (ASX: CSL) shares are having a week to forget.
Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock have closed in the red every day this week so far, leading up to Friday's opening bell.
The stock closed down 6.88% yesterday, trading for $152.19 a share.
That followed on the 4.6% losses suffered on Wednesday as investors pored over the company's half-year earnings results. Investors also responded negatively to news, reported after market close on Tuesday, that Paul McKenzie was stepping down from his three-year stint as CEO.
The four consecutive days of losses see CSL shares down 15.68% since last Friday's close.
Which, according to Family Financial Solutions' Jabin Hallihan, could make today an opportune time to buy shares at a potential bargain (courtesy of The Bull).
Image source: Getty Images
Should you buy CSL shares today?
"CSL develops plasma therapies and vaccines for a global market," Hallihan said late last week, prior to CSL's results release and CEO departure news. "The company provides products to patients in more than 100 countries."
Hallihan noted, "The share price has fallen from $271.32 on August 18, 2025 to trade at $181.48 on February 5, 2026. Our fair value is $295 a share."
At Thursday's close of $152.19 a share, this sees the ASX 200 biotech stock trading 94% below Hallihan's fair value estimate.
Commenting on his buy recommendation on CSL shares, Hallihan concluded:
Short term earnings noise obscures a high-quality plasma franchise with structural demand growth. In a bull market, valuation normalisation and quality should deliver strong upside moving forward.
What's been happening with the ASX 200 biotech stock?
As mentioned up top, it was a big news week for CSL shares.
On the leadership front, McKenzie abruptly retired as CEO and managing director effective on Tuesday. The board appointed Gordon Naylor, former CFO and president of CSL's Seqirus business, as interim CEO and managing director. Naylor took over the reins on Wednesday.
As for the results for the six months to 31 December, the company reported revenue of US$8.3 billion, down 4% year on year on a constant currency basis.
On the bottom line, CSL saw a 7% decline in underlying net profit after tax and amortisation (NPATA) to US$1.9 billion.
Commenting on the half-year results that pressured CSL shares, CFO Ken Lim said, "We are clearly not satisfied with our performance and have implemented a number of initiatives to drive stronger growth going forward."
Looking ahead, Lim added:
We continued to advance our broader transformation strategy, making strong progress on our cost efficiency initiatives and strengthening the foundations of the business.
We invested in growth opportunities including our strategic collaboration with VarmX. This will deliver enhanced growth, profitability and shareholder returns.
CSL also increased its share buyback program from US$500 million to US$750 million.
